CHIMERIC
THERAPEUTICS

APPENDIX 4C

Quarter Ended 31 December 2024

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **31 JANUARY 2025**

QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 31 DECEMBER 2024

Sydney, Australia, 31 January 2025: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 December 2024.

- First three patients dosed in Phase 1/2 clinical trial of CHM CDH17 Car-T Cell Therapy
- Phase 1B ADVENT-AML trial progressed to include newly diagnosed AML patients, with up to 20 participants to be enrolled
- Complete response reported in an AML patient 28 days after starting treatment in the CHM CORE-NK + Vactosertib Phase 1B trial.
- $5M raise completed through a two-tranche placement to support the CHM CDH17 CAR-T Phase 1/2 trial and other ongoing programs
- Dr Rebecca McQualter appointed Chief Executive Officer

FIRST THREE PATIENTS DOSED IN PHASE 1/2 CLINICAL TRIAL OF CHM CDH17

Chimeric's lead program, CHM CDH17, is a world leading CDH17-directed CAR-T cell therapy designed to treat patients with gastrointestinal (GI) cancers. The first-in-human clinical trial of CHM CDH17 is recruiting subjects at US cancer centres with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours.

The first three patients have now been dosed at Sarah Cannon Research Institute in Nashville, Tennessee and Upenn Oncology in Philadelphia, Pennsylvania. Interim results from the trial will be provided when sufficient data becomes available. Chimeric has also successfully completed five manufacturing runs with its contract manufacturer.

The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate. The Phase 1 portion of this study is expected to enrol 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.

CHM CDH17 is a unique 3rd generation, novel CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumours.

PHASE 1B CHM CORE-NK TRIAL ACHIEVES COMPLETE RESPONSE, ADVANCES TO INITIATE TREATMENT OF NEWLY DIAGNOSED AML PATIENTS

The Phase 1B ADVENT-AML clinical trial of Chimeric's CHM CORE-NK platform technology has advanced to now include newly diagnosed AML patients who are elderly or ineligible for intensive chemotherapy or stem cell transplantation. This follows the successful completion of the dose-finding phase, which enrolled relapsed or refractory (failed) AML patients and confirmed the safety of the CORE-NK cell therapy in combination with standard treatments (Azacitidine and Venetoclax). No dose-limiting toxicities or unexpected\ safety concerns were identified during this phase.

The trial, conducted at MD Anderson Cancer Center, is now enrolling up to 20 newly diagnosed AML participants for the next phase. CORE-NK cells, developed at Case Western Reserve University, are cryopreserved to enable "off-the-shelf" accessibility, providing a scalable and innovative approach to treatment. This is the first clinical trial to evaluate the combination of CORE-NK cell therapy with the standard of care for AML, aiming to improve outcomes for patients who are unsuitable for more intensive treatments.

During October it was also announced that the trial achieved a complete response (no evidence of cancer) in an AML patient, 28 days after starting treatment with the CHM CORE-NK + Vactosertib combination. This was the first patient treated in the blood cancer arm of the trial, being led by Dr Eva Selfridge at the UH Seidman Cancer Center in Ohio.

The trial follows the Phase 1A study, which showed safety and efficacy of CORE-NK cells in blood cancers. The current trial combines these NK cells with Vactosertib, a TGF-β receptor inhibitor, to test their effectiveness in advanced colorectal and blood cancers. It is planned to enrol 12 patients in the study.

CORPORATE

INVESTOR WEBINAR

Following the Company's capital raising process, it held an investor webinar to update its shareholders, investors and other interested parties. A replay can be viewed at: https://us02web.zoom.us/webinar/register/WN_6SRe5FNkTMmUEC-uBav93g

DR REBECCA MCQUALTER APPOINTED CEO

In November, then Chief Operating Officer Dr Rebecca McQualter was appointed as Chief Executive Officer. Dr McQualter joined the Company in May, bringing senior experience from

roles at Novartis, Amgen and GlaxoSmithKline. Dr McQualter holds a Doctor of Philosophy in Cell Therapy and Regenerative Medicine from Monash University.

FINANCIALS

An Appendix 4C Quarterly Cash Flow report is attached to this announcement.

As detailed in the attached ASX Appendix 4C the Company had $5.07 million in cash and cash equivalents at 31 December 2023, increasing from $3.10 million at the end of the prior quarter.

The net cash used in Operating Activities during the quarter was $0.11 million as the company received $4.17 million from the research and development (R&D) tax incentive as detailed in the Appendix 4C.

The net financing inflows for the quarter was $2.03 million as the company successfully raised a further $4.00 million through closing its two-tranche placement. In the quarter the Company also repaid its $1.56 million advance on its R&D rebate.

In accordance with Listing Rule 4.7C, payments made to related parties and their associated included in items 6.1 of the Appendix 4C include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses. The Board has focused on prudent management of cash and as a result careful cost cutting strategy projected total expenditure has and will continue to be reduced.

$5 MILLION PLACEMENT TO PROGRESS CHM CDH17 THROUGH PHASE 1/2 TRIAL

During the quarter, Chimeric raised $5 million through a two-tranche placement to professional, and sophisticated investors at $0.008 per share. Approximately 625 million new fully paid ordinary shares were issued under the placement, in addition to one unlisted option (with an exercise price of $0.008, expiring 12 months from the grant date) granted for every one placement share issued.

The proceeds will primarily support the CHM CDH17 CAR-T program, which is currently in a Phase 1/2 clinical trial targeting neuroendocrine tumors, colorectal cancer, and gastric cancer. The trial, with sites at the Sarah Cannon Cancer Centre and the University of Pennsylvania, has commenced dosing patients and aims to enrol up to 15 participants by the end of FY25.

Additional funds will support and the CORE NK platform, which is advancing through two Phase 1B trials and the CHM CLTX CAR-T therapy, under evaluation in a Phase 1B trial for glioblastoma.

CHIMERIC RECEIVES $4.17M R&D TAX INCENTIVE

During the quarter the Company received a research and development (R&D) tax incentive refund of $4,172,342 under the Australian Government's R&D Tax Incentive. The Australian Government R&D tax incentive provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%. The refund to Chimeric is in recognition of the Company's R&D activities during the 2024 financial year.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper

CONTACT

Investors
Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Chimeric Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
68 638 835 828	31 December 2024

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (6 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers (inclusive of GST)	-	-
1.2	Payments for (inclusive of GST)		
	(a) research and development	(1,897)	(2,743)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs*	(1,747)	(3,021)
	(f) administration and corporate costs	(698)	(1,122)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	15	26
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	4,172	4,172
1.8	Other (provide details if material)	42	82
1.9	**Net cash from / (used in) operating activities**	**(113)**	**(2,606)**

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	4,000	5,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(325)	(325)
3.5	Proceeds from borrowings	-	1,562
3.6	Repayment of borrowings	(1,562)	(1,562)
3.7	Transaction costs related to loans and borrowings	(86)	(86)
3.8	Dividends paid	-	-
3.9	Other – payments of licence fee liabilities	-	-
3.10	**Net cash from / (used in) financing activities**	**2,027**	**4,589**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	3,101	3,053
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(113)	(2,606)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,027	4,589
4.5	Effect of movement in exchange rates on cash held	53	32
4.6	**Cash and cash equivalents at end of period**	**5,068**	**5,068**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	5,068	3,101
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**5,068**	**3,101**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	313
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(113)
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,068
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	5,068
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	45

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

- The Company does not expect to maintain the current level of net operating cash flows as the Company received a $4m R&D tax incentive rebate relating to the fiscal year ending 30 June 2024 during the December 2024 quarter.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

- N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

- N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 January 2025

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

CHIMERIC
THERAPEUTICS

+61 3 9824 5254
info@chimerictherapeutics.com

Chimeric Therapeutics Limited
ACN 638 835 828

ASX: CHM